$0.38
−7.10%Price chart
Mar 13Mar 18Mar 23Mar 26Mar 31Apr 6Apr 9Apr 14
Key dataApr 14, 2026
Open$0.38
From 52W high−81.04%
Volume5.14M
Market cap$22.64M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataApr 14, 2026
Open
$0.38
From 52W high
−81.04%
Volume
5.14M
Market cap
$22.64M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
P/E (TTM)
—
RSI (14)
47.6
MomentumView details →
1D Return
−7.10%
YTD Return
+19.69%
SummaryUpdated Sep 1, 2025
Klotho Neurosciences, Inc. (NASDAQ:KLTO) is an early-stage biopharmaceutical company focused on developing gene therapies for neurodegenerative diseases, cancer, and cardiovascular disorders. Originally founded as Anew Medical, Inc., the company rebranded to Klotho Neurosciences in September 2024 to reflect its focus on therapies based on the klotho protein, which plays a crucial role in aging and longevity. Headquartered in Omaha, Nebraska, the company is currently in the preclinical development stage with no approved products or revenue generation.
Similar companies
Latest newsMore news →
Greenland Mines formed a Strategic Advisory Board with three industry leaders to support project strategy, studies, permitting and partnerships.6d agoJason Hawkins was appointed to the Board of Greenland Mines Ltd effective September 8, 2026.9d agoShalom Hirschman and Riad El-Dada resigned from the Board of Directors of Greenland Mines Ltd effective September 8, 2026.9d ago